Alpha-sarcoglycanopathy presenting as myalgia and hyperCKemia in two adults with a long-term follow-up. Case reports

Claudia Dosi¹, Anna Rubegni¹, Denise Cassandrini¹, Alessandro Malandrini¹, Lorenzo Maggi³, M. Alice Donati⁴, Filippo M. Santorelli¹

¹IRCCS Fondazione Stella Maris, Pisa, Italy; ²Department of Medicine, Surgery and Neurosciences, University of Siena, Italy; ³Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milan, Italy; ⁴Metabolic Disease Unit, AOU Meyer Children Hospital, Florence, Italy

Two patients with a paucisymptomatic hyperCKemia underwent a skeletal muscle biopsy and massive gene panel to investigate mutations associated with inherited muscle disorders. In the SGCA gene, sequence analyses revealed a homozygous c.850C>T/p.Arg284Cys in patient 1 and two heterozygous variants (c.739G>A/p. Val247Met and c.850C>T/p.Arg284Cys) in patient 2. Combination of histology and immunofluorescence studies showed minimal changes for muscular proteins including the α-sarcoglycan. These two cases highlight the advantages of next-generation sequencing in the differential diagnosis of mild myopathic conditions before considering the more invasive muscle biopsy in sarcoglycanopathies.

Key words: hyperCKemia, Next Generation Sequencing, muscle biopsy, SGCA

Introduction

Elevated blood creatine kinase (CK) is among the signs most likely to prompt referral of children and adults to neuromuscular specialists in Europe (ean.org/Guideline-Reference-Center.2699.0.html). Current international guidelines define persistent hyperCKemia as the presence of serum values more than 1.5 times the upper limit of normal in at least two independent measurements ¹, but this definition does not consider the presence or absence of associated clinical manifestations. Indeed, asymptomatic hyperCKemia can run in families long before its chance detection. On the other hand, recent advances clarifying the genetic etiologies of muscle disorders have been crucial in reducing the number of undefined hyperCKemia cases and expanding the spectrum of manifestations associated with the condition. For example, using a multiple gene panel and next-generation sequencing (NGS) in a small cohort of undiagnosed patients with hyperCKemia, we recently detected a subset of paucisymptomatic individuals harboring biallelic variants in known muscular dystrophy genes ².

We herein discuss two patients who showed persistent high serum CK levels and occasional exercise intolerance and myalgia in the absence of other neurological signs over a long-term follow-up. Both cases harbored biallelic variants of predicted pathogenic significance in SGCA. Patient

© Gaetano Conte Academy - Mediterranean Society of Myology

OPEN ACCESS

This is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en
1 is 36-year-old man with an unremarkable prenatal and perinatal history and normal psychomotor development. He was first evaluated, because of persistent high CK levels at rest (ranging from 1700 to 8000 UI/L), at the age of 10 years. At that time his neuromuscular examination was unremarkable. At the age of 20, having more recently developed exercise intolerance and sporadic myoglobinuria after competitive exercise, he experienced two episodes of atrial fibrillation. After remission of his symptoms, he recovered completely and is still able to cycle and run for long distances, albeit with occasional muscle pain. At his latest neurological examination, which was unremarkable, moderate calf hypertrophy was observed.

Patient 2 is a 31-year-old woman with a history, from early childhood, of hyperCKemia (ranging from 500 UI/L to 4500 UI/L), almost invariably accompanied by myalgia and exercise intolerance. These complaints persisted unchanged over time in a context of normal psychomotor development. Her family history was significant for an asymptomatic uncle who had persistent high serum CK levels. The patient has undergone annual specialist evaluations over the past 25 years. Her latest neurological, cardiac and respiratory examinations were normal, but we observed minimal hypertrophy of the calves. A muscle MRI study of lower girdle muscles was unremarkable but we observed fat infiltration in the right gluteus minimus (Fig. 1).

In the course of their lives, both patients have twice undergone muscle biopsy; all these examinations showed only minimal myopathic changes on histological assessment and normal immunofluorescence staining for muscle proteins including α-sarcoglycan (Fig. 2). Using a massive gene panel to investigate genes associated with inherited muscle disorders, we identified a homozygous c.850C>T/p.Arg284Cys mutation in patient 1 and two variants (c.739G>A/p.Val247Met and c.850C>T/p.Arg284Cys) in compound heterozygosity in patient 2 in the SGCA gene. Both variants were predictably deleterious, with high CADD scores (https://cadd.gs.washington.edu/); both segregated with the disease status in the respective families (Fig. 3), and met the American College of Medical Genetics and Genomics recommended criteria for possible pathogenic variants.

The mutations detected in this study have already been reported in association with myoglobinuria, high CK levels and limb girdle muscle weakness. Our report adds to the evidence that hyperCKemia can be the presenting feature of a sarcoglycanopathy associated with myoglobinuria, exercise-induced myalgia and/or rhabdomyolysis. Contrary to previous reports, our long follow-up of these patients, characterized by unremarkable neurological examinations and only minimal, pseudometabolic complaints, suggests that a sarcoglycanopathy can go undetected in patients and families. This suggests that caution should be exercised before dismissing cases of asymptomatic hyperCKemia as idiopathic, and that such cases should be monitored closely for potential severe myoglobinuria and rhabdomyolysis following minimal exercise. Our report is also significant as it might draw attention of neuromuscular experts to the value of the NGS approach, which can play a fundamental diagnostic role and may obviate the need to perform muscle biopsies in patients with asymptomatic hyperCKemia. In our patients, the combination of muscle histology and immunofluorescence alone would not have identified the cause of the symptoms. This suggests that a first-tier NGS screening in blood should be favoured, especially in children, before considering the more invasive muscle biopsy option, which could instead be kept as a second-level diagnostic approach to be used in the event of uncertain or negative results. Whether other factors besides the genetic mutation influence phenotypic manifestations in sarcoglycanopathies remains unclear and should be further investigated.

Acknowledgments

We are indebted to Catherine J. Wrenn for the expert editing of the manuscript and critical advice. This study
Figure 2. Myopathological changes in patient 2. Hematoxylin and eosin (A) and Gomori trichrome (B) staining demonstrating slight variation in fiber size and some central nuclei. Immunofluorescence labeling of α-sarcoglycan showing decreased expression in patient 2 (D) compared with an age-matched healthy control (C).

Figure 3(A-B) Genetic studies. Pedigree of the family and electropherograms showing the segregation of the variants in the family members.
received partial financial support from the Italian Ministry of Health-Ricerca Corrente, (to FMS) and 5X1000 (to FM), Fondazione Telethon (Grant numbers GUP09004). This work was also supported by a grant from Regione Toscana (FAS Salute 2018, InGene2.0) and performed in the frame of the Euro-NMD network.

References

1. Kyriakides T, Angelini C, Schaefer J, et al. European Federation of Neurological Societies. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol 2010;17:767-73. https://doi.org/10.1111/j.1468-1331.2010.03012.x PMID: 20402744

2. Rubegni A, Malandrini A, Dosi C, et al. Next-generation sequencing approach to hyperCKemia: a 2-year cohort study. Neurol Genet 2019;5(5):e352. https://doi.org/10.1212/NXG.0000000000000352

3. Richards S, Aziz N, Bale S, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-24. https://doi.org/10.1038/gim.2015.30 PMID: 25741868; PMCID: PMC4544753

4. Piccolo F, Roberds SL, Jeanpierre M, et al. Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity. Nat Genet 1995;10:243-5. https://doi.org/10.1038/ng0695-243. Erratum in: Nat Genet 1995 Sep 11(1):104. PMID: 7663524

5. Duggan DJ, Gorospe JR, Fanin M, et al. Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med 1997;336:618-24. https://doi.org/10.1056/NEJM199702273360904

6. Silvestri NJ, Wolfe GI. Asymptomatic/pauci-symptomatic creatine kinase elevations (hyperckemia). Muscle Nerve 2013;47:805-15. https://doi.org/10.1002/mus.23755

7. Malandrini A, Orrico A, Gaudiano C, et al. Muscle biopsy and in vitro contracture test in subjects with idiopathic HyperCKemia. Anesthesiology 2008;109:625-8. https://doi.org/10.1097/ALN.0b013e3181862a0d. PMID: 18813041

8. Filosto M, Tonin P, Vattemi G, et al. The role of muscle biopsy in investigating isolated muscle pain. Neurology 2007;68:181-6. https://doi.org/10.1212/01.wnl.0000252252.29532.cc